JMP Securities Reiterates Market Outperform on Halozyme Therapeutics, Maintains $72 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a price target of $72.
January 18, 2024 | 4:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst maintains a bullish 'Market Outperform' rating on Halozyme Therapeutics with a $72 price target.
The reiteration of a 'Market Outperform' rating and the maintenance of a $72 price target by a reputable analyst could lead to increased investor confidence and a potential short-term positive impact on Halozyme Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100